Skip to content

EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY

EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07384663
Enrollment
112
Registered
2026-02-03
Start date
2025-06-01
Completion date
2025-11-30
Last updated
2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anaemia in Childbirth

Keywords

Anaemia, Iron Supplementation, Pregnancy

Brief summary

This study was planned to compare outcomes of IV versus oral iron in the treatment of iron deficiency anemia during pregnancy. This study was used to investigate the efficacy of two new formulations of iron both in IV and oral form with fewer side effects. We compared the efficacy of Intravenous Ferric Carboxymaltose with Oral polysaccharide iron complex. The better mode of treatment will be administered in future to treat this condition, that will surely improve the fetal and maternal outcome.

Interventions

Single dose of 500 mg Ferric carboxymaltose diluted in 100 mL 0.9% sodium chloride (or if pre-pregnancy body weight is \< 50 kg the dose was 10 mg/kg based on pre-pregnancy body weight). Infusions was administered over approximately 20 min and participants were observed for adverse reactions during, and 30 min after, the end of the infusion.

Polysaccharide iron complex 150 mg capsule was administered daily till 4 weeks

Sponsors

Dr Salaha Azam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women aged 18 -45 years; * Second trimester (gestational age 14-21 weeks); * Females having hemoglobin level of \< 11 g/dL

Exclusion criteria

* Multiple pregnancies, * A history of multiple allergies, known hypersensitivity to any of the excipients in the investigational drugs, * Active infections * Recent red blood cell (RBC) transfusion * Thalassemia minor

Design outcomes

Primary

MeasureTime frameDescription
Blood Haemoglobin Levels4 weeksNon Anaemic Levels are labelled as (Hb ≥ 11.0 g/dL) at 4th week

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026